Feasibility of Monitoring Response to Metastatic Prostate Cancer Treatment with a Methylation-Based Circulating Tumor DNA Approach

Feasibility of Monitoring Response to Metastatic Prostate Cancer Treatment with a Methylation-Based Circulating Tumor DNA Approach

Background: Metastatic prostate cancer (mPCA) poses challenges in treatment response assessment, particularly in cases where prostate-specific antigen (PSA) levels do not reliably indicate a response. Liquid biopsy, focusing on circulating cell-free DNA (ccfDNA) methylation analysis as a proxy for c...

Full description

Bibliographic Details
Main Authors: Thomas Büttner, Dimo Dietrich, Romina Zarbl, Niklas Klümper, Jörg Ellinger, Philipp Krausewitz, Manuel Ritter
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Cancers
Subjects:
metastatic prostate cancer
biomarkers
SHOX2
SEPT9
liquid biopsy
Online Access:https://www.mdpi.com/2072-6694/16/3/482

Internet

https://www.mdpi.com/2072-6694/16/3/482

Similar Items